TheraRadar
← Back
Data updated: May 24, 2026

VIIV HLTHCARE

Biotech

VIIV HLTHCARE is a biotechnology company focused on Infectious Disease, Immunology. Key products include TIVICAY.

1987
Since
19
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
12 Small Molecules
Novel Drugs (2020-2021):
2 Novel Approvals 1 First-in-Class 1 Breakthrough

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Infectious Disease 67%
12 drugs
Immunology 33%
6 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • DOVATO leads revenue
  • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis
View patent timeline →

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Compare with competitor →
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling